HOME > Entacapone
|Packaging Details:||As required|
|Delivery Detail:||As required|
|Anti-Parkinson’s disease drugs||Entacapone is an anti-Parkinson’s disease drug which is successfully developed by Orion Pharma company in Swedish. It is a highly selective potent catechol-O-methyltransferase (COMT) inhibitor, rarely penetrating the blood – brain barrier, and primarily acting in the intestinal tract. It is dose-dependent to decrease levels of 3-OMD in serum and the brain, increasing levodopa, dopamine and DOPAC levels in the brain and significantly reducing the dose which is required to increase dopamine concentration in striatal. Levodopa and carbidopa combining with COMTI can significantly increase the bioavailability of levodopa (3-4 times). Activity of COMTI in red blood cell is reversible. When in 800mg dose, the maximum inhibitory activity is up to 82%, so Entacapone combines with levodopa and carbidopa, which can be used for adjuvant therapy of idiopathic Parkinson’s disease.|
This product is rapid oral absorption, the bioavailability is a dose-dependent with the range of 30% to 45%. In the range of 5 ~ 800 mg, pharmacokinetics of Entacapone (abbreviation: Ent) is linear, peak plasma concentration is related to AUC and dose. Food does not affect the absorption of this product, 98% Ent combines with plasma albumin, rarely distributing in tissues. In patients with Parkinson disease (abbreviated: PD), and is required to take levodopa / carbidopa, the peak concentration of Ent arrives within 1 ~ 2h. The rate of Ent through the blood-brain barrier is low, the plasma elimination half-life is 1.5 ~ 3.5h. After oral administration, Ent (E- configuration) is metabolized to Z- isomer in the blood and is present in plasma and red blood cells. Z- isomer has little impact on the clinical efficacy. Its drug – time curve is similar to Ent. Z-Ent accounts for about 5% of the total AUC. Ent and Z-Ent are acidified by glucose in the liver. After metabolism of Ent: 10% excreted in the urine, 90% of Ent excreted in the feces, only 0.2% excreted in the urine in phony drugs. While taking levodopa in PD patients, and oral Ent 200 mg after elimination half-life of about 1 h, the body has no savings.
Pharmacokinetic study shows that in healthy persons and patients with PD, Ent can increase the bioavailability of levodopa. In the short-term PD patients taking Ent, AUC of levodopa increase 25%, while the long-term taking Ent can increase 50%. AUC of 3-OMD relatively reduces 60%. In these studies, they found that plasma peak time of levodopa will be extended. Single dose of Entacapone (while not taking levodopa / carbidopa), in patients with liver disease, the patient’s AUC and Cmax is 2 times of the patients with normal liver function. We should adjust the dosage of the patient. In patients with mild to moderate kidney disease, it is not necessary to adjust the dosage. Kidney patients receiving dialysis can extend dosing interval.
|application||As COMT inhibitors, it is used to treat Parkinson’s disease.|
|Usage||(E)-Isomer of Entacapone polymorphic form A. Peripherally acting inhibitor of catechol-O-methyl transferase (COMT), an enzyme involved in the metabolism of catecholamine neurotransmitters and related drugs. Antiparkinsonian. This compound belongs to the cinnamic acid amides. These are amides of cinnamic acids. Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-|
We provide Flexible payment (O/A 180 days) also with low price, good quality and service!
High Quality & Best Service
If any questions, plz feel free to contact us.
COPYRIGHT ©2010 GINVENT CHEMICAL CO., LTD. ALL RIGHTS RESERVED
ADD: No.5 Jinzhong road, Huli district, Xiamen, China
TEL : +86-592-5510958 FAX : +86-592-5510958 E-MAIL : SALES@GINVENTCHEM.COM